8-K
filed August 12, 2024, 7:59 PM ET
ticker LSTA
CIK 0000320017
earnings
confidence high
sentiment neutral
materiality 0.65
Lisata Therapeutics Q2 2024 net loss $5.0M; ASCEND Phase 2b top-line data expected Q4 2024
LISATA THERAPEUTICS, INC.
2024-Q2 EPS reported
-$1.26
- Net loss $5.0M in Q2 2024 vs $4.0M in Q2 2023; operating expenses down 19.7% to $5.5M.
- Cash & equivalents $38.3M; funding into early 2026 covering all active trials to data milestones.
- Phase 2b ASCEND trial (certepetide + chemo in mPDAC) top-line results from 95-patient Cohort A on track for Q4 2024.
- BOLSTER Phase 2a in 1L cholangiocarcinoma fully enrolled ahead of plan; topline data mid-2025; 2L cohort added.
- Certepetide received U.S. FDA Orphan Drug and Rare Pediatric Disease designations for osteosarcoma in H1 2024.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0000320017-24-000049
- form_type
- 8-K
- ticker
- LSTA
- cik
- 0000320017
- company_name
- LISATA THERAPEUTICS, INC.
- filed_at
- 2024-08-12T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:15.491016+00:00
- generated_at
- 2026-05-31T10:12:02.386059+00:00
- sec_items
- ["2.02", "7.01", "9.01"]
- event_type
- earnings
- sentiment
- neutral
- materiality_score
- 0.65
- calibrated_materiality_score
- 0.65
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0000320017-24-000049
- json_url
- https://secwatch.observer/filing/0000320017-24-000049.json
- markdown_url
- https://secwatch.observer/filing/0000320017-24-000049.md
- text_url
- https://secwatch.observer/filing/0000320017-24-000049.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/320017/000032001724000049/0000320017-24-000049-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/320017/000032001724000049/clbs-20240812.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
FNGR
FingerMotion FY2026 revenue down 32% to $24.1M; net loss widens to $7.0M
FingerMotion, Inc.
May 29, 2026, 5:12 PM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
ADSK
Autodesk Q1 FY27 revenue up 18% to $1.93B, GAAP EPS $2.32; acquires MaintainX
Autodesk, Inc.
May 28, 2026, 4:14 PM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
OKTA
Okta Q1 FY2027 rev $765M (+11% YoY); GAAP net income $74M; free cash flow $271M
Okta, Inc.
May 28, 2026, 4:03 PM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
SOTK
Sono-Tek reports FY2026 net income up 42% to $1.8M; gross margin expands to 51%
SONO TEK CORP
May 28, 2026, 7:10 AM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
KSS
Kohl's Q1 net loss $14M; comparable sales down 1.1% YoY; affirms FY outlook
KOHLS Corp
May 28, 2026, 7:00 AM ET
earnings
Items 2.02, 7.01, 8.01, 9.01
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
DLTR
Dollar Tree Q1 net sales +7.2%, comp +3.5%, adj EPS $1.74 (+38%), raises FY guidance
DOLLAR TREE, INC.
May 28, 2026, 6:31 AM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
BBWI
BBWI Q1 sales down 3%, adjusted EPS $0.32 beats guidance; CFO Boratto to step down June 12
Bath & Body Works, Inc.
May 27, 2026, 7:12 AM ET
earnings
Items 2.02, 7.01, 5.02, 9.01
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
SMTC
Semtech reports record Q1 net sales $291M, GAAP EPS $0.27, adjusted EPS $0.51
SEMTECH CORP
May 26, 2026, 4:07 PM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.